In recurrent pouchitis after two courses of antibiotics, is a short course of oral corticosteroids or biologic therapy such as vedolizumab preferred

What is known

- Both a short course of oral corticosteroids and vedolizumab are second-line options for chronic antibiotic-refractory (or antibiotic-dependent) pouchitis, and guideline algorithms place a short course of corticosteroids (preferably controlled-release budesonide) before, not versus, biologics, sequencing budesonide/anti-inflammatories/immunomodulators ahead of biologics and reserving biologics for lack of response. ^1,2 - Corticosteroids are suggested for recurrent pouchitis with inadequate antibiotic response but on very-low-certainty evidence and for short duration (<8–12 weeks). A conditional AGA suggestion resting on two case series with pooled response ~77%. While vedolizumab is the only agent with RCT support (EARNEST, 51 vs 51) and is the IIPC/AGA-preferred biologic for chronic antibiotic-refractory pouchitis. ^2,3 - Before escalating, secondary causes (NSAIDs, CDI/CMV, structural complications like leak, stricture, sinus, torsion) should be excluded and the diagnosis confirmed endoscopically.

What is unknown / caveats

- The framing is off: two antibiotic courses do not by themselves define the phenotype that either steroids or vedolizumab target - No head-to-head trial of corticosteroids vs vedolizumab for recurrent pouchitis - Corticosteroid evidence is very-low-certainty (two small case series); vedolizumab has one RCT - Antibiotic-dependent vs antibiotic-refractory phenotype not distinguishable from 'two antibiotic courses' alone - The corpus offers no direct comparison, so relative superiority of a steroid course versus vedolizumab cannot be established - Phenotype (antibiotic-dependent vs refractory), prior therapy exposure, and exclusion of secondary/structural causes drive the actual sequencing decision, this belongs to the treating team.

## References

1. Tome J, Raffals LE, Pardi DS. Management of Acute and Chronic Pouchitis. Dis Colon Rectum. 2022;65:S69-S76. PMID: 35905290.

2. Barnes EL, Agrawal M, Syal G, Ananthakrishnan AN, Cohen BL, Haydek JP, Al Kazzi ES, Eisenstein S, Hashash JG, Sultan SS, Raffals LE, Singh S, AGA Clinical Guidelines Committee. Electronic address: C. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders. Gastroenterology. 2024;166(1):59-85. PMID: 38128971.

3. Mesonero F, Zabana Y, Fernández-Clotet A, Leo-Carnerero E, Caballol B, Núñez A, García MJ, Bertoletti F, Bastida G, Suris G, Casis B, Ferreiro-Iglesias R, Calafat M, Jiménez I, Miranda-Bautista J, Lamuela LJ, Fajardo I, Torrealba L, Nájera R, Sáiz-Chumillas RM, González-Partida I, Vicuña M, García-Morales N, Gutiérrez A, López-García A, Benítez JM, Rubín de Célix C, Tejido C, Brunet-Mas E, Hernandez-Camba A, Ferrer CS, Rodríguez-Lago I, Piqueras M, Castaño A, Ramos L, Sobrino A, Rodríguez-Grau MC, Elosua A, Montoro-Huguet MA, Baltar R, Huguet JM, Hermida B, Caballero-Mateos A, Sánchez-Guillén L, Bouhmidi A, Pajares R, Baston-Rey I, López-Sanromán A, Albillos A, Barreiro-de Acosta M. Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU. Ther Adv Gastroenterol. 2026;19:17562848261422373. PMID: 41732330.

For educational use only, not a substitute for clinical judgement or medical advice. Consult qualified clinicians for diagnosis and treatment decisions. This tool may contain errors; use the flag button below to report inaccurate or harmful content.

---

_Draft, generated by the IBDology RAG and not yet clinician-reviewed. Answers are grounded in the retrieved literature listed above; a high faithfulness score means the answer matches its sources, not that the sources are correct._